Research Reports | Market Assessment
October 2015

Nephrology in Chronic Kidney Disease Non-Dialysis | Chart Trends | France, Germany, and Italy | 2015

This report leverages physician insights, as well as patient chart data, to provide the most up-to-date information about chronic kidney disease non-dialysis (CKD-ND) patient care in France, Germany, and Italy (EU3), including patient demographics and the use of medications. Our in-depth analysis of CKD-ND medications spans a wide range of variables, including product initiation, dosing, switching, and concomitant therapy; coverage includes erythropoiesis-stimulating agents (ESAs), IV iron, oral iron, phosphate binders, nutritional vitamin D (NVD), active vitamin D (AVD), and Amgen’s Mimpara (cinacalcet). By comparing what nephrologists report about patient care with actual patient records, we uncover gaps in intended versus actual care and reveal opportunities for the expanded use of current and emerging therapies. In our new section on products in development, we cover nine emerging therapies. This section allows manufacturers to see profiles of those patients who would be considered to start on the emerging therapy, assuming that it receives regulatory approval.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports